Back to top

NRx Pharmaceuticals re-files abbreviated NDA for KETAFR

NRx Pharmaceuticals (NRXP), “announced the re-filing of its Abbreviated New Drug Application to the U.S. Food and Drug Administration for KETAFREE(...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

NRx Pharmaceuticals, Inc. (NRXP)